New research reveals that race and ethnicity significantly influence how myasthenia gravis (MG) manifests in U.S. patients, with African American and Hispanic individuals developing the autoimmune condition at much younger ages and experiencing more severe initial symptoms. The study, drawing from two large national databases, highlights a stark divide…

The U.S. Food and Drug Administration (FDA) granted priority review to Argenx’s application seeking to expand the approval of Vyvgart (efgartigimod alfa-fcab) to adults with generalized myasthenia gravis (gMG) who test negative for anti-acetylcholine receptor (AChR) antibodies. If the supplemental biologics license application is approved, the infusion…

Dysphagia, or difficulty swallowing, is highly prevalent in people with myasthenia gravis (MG) and may be associated with severe complications, including lung infections caused by food aspiration into the airways. That is according to a review of studies assessing dysphagia in MG patients using objective instrumental tests and subjective…

Women with myasthenia gravis (MG) have a higher risk of pregnancy complications, particularly preeclampsia, and their babies are more likely to be born prematurely and small for their gestational age, according to a study in the U.S. Preeclampsia is a serious pregnancy complication marked by new-onset high blood pressure…

Starting rituximab earlier after the onset of generalized myasthenia gravis (gMG) may be associated with better long-term outcomes, including fewer hospital admissions due to disease worsening and the need for rescue treatments. That’s according to up to five-year results from a follow-up study of participants in the…

Vyvgart (efgartigimod) combined with a low 250 mg dose of the glucocorticoid methylprednisolone may offer a safer and equally effective treatment option for people with severe generalized myasthenia gravis (gMG), according to a new study from China. gMG patients treated with this combination showed comparable reductions in disease severity…

In 2025, Myasthenia Gravis News delivered readers timely reporting on research, treatments, and clinical trials for myasthenia gravis (MG). We have compiled the 10 most-read stories for a recap of the year, each accompanied by a brief summary. As we enter 2026, we look forward to continuing our…

The approved therapy Zilbrysq (zilucoplan) safely and effectively eases symptoms and improves function and quality of life for people with generalized myasthenia gravis (gMG) who are positive for antibodies against the acetylcholine receptor (AChR) protein. These are the main findings of a real-world study from Italy, which also showed…

Adding a single infusion of Vyvgart (efgartigimod alfa-fcab) to treatment typically given before a thymectomy, or the surgical removal of the thymus gland, results in greater clinical and laboratory improvements in people with myasthenia gravis (MG). That’s according to a small, single-center study in China, which showed that…

A study of myasthenia gravis (MG) patients lends support to “ongoing efforts to develop efficacious MG-specific treatments with minimal short- and long-term adverse effects,” researchers said. The U.S.-based study found that MG patients aged 65 and older have higher rates of death than those without the disease, mainly due to…